Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the shares after the company announced Phase 2b topline data from ...

H.C. Wainwright raised the firm’s price target on Coinbase (COIN) to $330 from $255 and keeps a Buy rating on the shares. President Donald ...

D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...

H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The ...

Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Viking Therapeutics in a research note issued on Thursday, February 6th. HC Wainwright analyst J. Pantginis expects that ...

Fintel reports that on February 7, 2025, HC Wainwright & Co. initiated coverage of Vertical Aerospace (NYSE:EVTL) with a Buy recommendation. As of January 28, 2025, the average one-year price ...

In this article, we are going to take a look at where Knightscope, Inc. (NASDAQ:KSCP) stands against the other AI stocks. In the latest news in AI, SoftBank Group CEO Masayoshi Son said that he has ...

Fintel reports that on January 10, 2025, HC Wainwright & Co. initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a Buy recommendation. As of March 27, 2023, the average one-year ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...